Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Raymund R. Razonable, Colin Pawlowski, John C. O'Horo, Lori L. Arndt, Richard Arndt, Dennis M. Bierle, Molly Destro Borgen, Sara N. Hanson, Michelle C. Hedin, Patrick Lenehan, Arjun Puranik, Maria T. Seville, Leigh L. Speicher, Sidna M. Tulledge-Scheitel, A. J. Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, Ravindra Ganesh

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Real-world clinical data to support the use of casirivimab–imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab–imdevimab treatment of mild to moderate COVID-19. Methods: A retrospective cohort of 696 patients who received casirivimab–imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 52–71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab–imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5–3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2–4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4–5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimab–imdevimab treatment was associated with a significantly lower rate of hospitalization. Funding: Mayo Clinic.

Original languageEnglish (US)
Article number101102
JournalEClinicalMedicine
Volume40
DOIs
StatePublished - Oct 2021

Keywords

  • Casirivimab
  • Covid-19
  • Imdevimab
  • Monoclonal antibodies
  • Outcomes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19'. Together they form a unique fingerprint.

Cite this